Instil Bio (TIL) EBIT (2020 - 2026)

Instil Bio has reported EBIT for 7 years, with the latest figure at -$5.6 million in Q2 2026.

• On a quarterly basis, EBIT rose 76.19% year-over-year to -$5.6 million in Q2 2026; TTM through Jun 2026 was -$37.2 million, a 58.45% increase from a year earlier, with the FY2025 full-year figure at -$78.6 million, down 6.85% from the prior year.
• EBIT was -$5.6 million for Q2 2026 at Instil Bio, up from -$7.0 million in the prior quarter.
• The five-year high for EBIT was -$5.6 million in Q2 2026, with the low at -$66.7 million in Q3 2023.
• Average EBIT over 5 years is -$30.6 million, with a median of -$23.5 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: EBIT tumbled 131.96% in 2022, then soared 77.08% in 2023.
• Over 5 years, EBIT stood at -$56.8 million in 2022, then jumped by 77.08% to -$13.0 million in 2023, then increased by 9.22% to -$11.8 million in 2024, then increased by 19.14% to -$9.6 million in 2025, then jumped by 41.6% to -$5.6 million in 2026.
• The last three EBIT figures came in at -$5.6 million (Q2 2026), -$7.0 million (Q1 2026), and -$9.6 million (Q4 2025), per Business Quant data.